OakChart

Cellectar Biosciences Inc

CLRBHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 2:01 PM ET

1.19-0.03 (-2.46%)
2026-11-11 20:11 CET
Market cap
11.53 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-25.85 USD m
Free cash flow, TTM
-24.62 USD m
EPS diluted, TTM
-3.61
P/E
-
Compare

Price

CLRB against its 20, 50 and 200-day averages
2050200beatmiss
1.002.003.00394K788KMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CLRBclose 1.1920-day 1.2150-day 1.68200-day 2.541.19

74.7% under the 52-week high of 4.70 on 5 May 2026. 52-week low 1.11 on 5 Nov 2026. Last 15 sessions, 23.4% high to low

Profile

CLRB
52-week range, 2% of the way up
1.114.70

Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124, which could detect tumors and metastases in a broad range of cancers, and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded on June 24, 1996 and is headquartered in Florham Park, NJ.

Employees11
IPOJun 14, 2005
Beta0.62
ATR, 14d0.11
Rel volume0.16
Short float2.35%
Insider own1.75%
Inst own35.03%

Snapshot

6 groups

Valuation

Index-
Market Cap11.25M
Enterprise Value-11.80M
Income-25.85M
Sales0.00M
Book/sh2.23
Cash/sh2.60
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees11
IPOJun 14, 2005

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.53
P/C0.46
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio4.44
Current Ratio4.44
Debt/Eq0.07
LT Debt/Eq0.07
Option/ShortNo / Yes

Earnings

EPS (ttm)-3.61
EPS next Y-1.97
EPS next Q-0.51
EPS this Y71.36%
EPS next Y17.72%
EPS next 5Y-
EPS past 3/5Y60.46% 48.41%
Sales past 3/5Y- -
EPS Y/Y TTM66.06%
Sales Y/Y TTM-
EPS Q/Q67.50%
Sales Q/Q-
EarningsNov 10 BMO
EPS/Sales Surpr.17.34% -

Ownership

Insider Own1.75%
Insider Trans11.72%
Inst Own35.03%
Inst Trans61.91%
ROA-116.54%
ROE-162.63%
ROIC-107.97%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-2.00%
SMA50-29.06%
SMA200-53.09%
Trades-

Technical

Shs Outstand10.04M
Shs Float9.29M
Short Float2.35%
Short Ratio2.33
Short Interest0.22M
52W High4.70 -74.68%
52W Low1.11 7.21%
Volatility10.19% 9.86%
ATR (14)0.11
RSI (14)37.93
Beta0.62
Rel Volume0.16
Avg Volume94.00K
Volume10,668

Performance

Perf Week-3.25%
Perf Month-14.39%
Perf Quarter-52.02%
Perf Half Y-59.52%
Perf YTD-59.66%
Perf Year-66.57%
Perf 3Y-97.96%
Perf 5Y-99.54%
Perf 10Y-99.98%
Recom1.00
Target Price11.50
Prev Close1.22
Price1.19
Change %-2.46%

Analyst ratings

latest 7 of 7
DateActionAnalystRating changeTargetImplied
May 15, 2026InitiatedLLadenburg ThalmannBuy$10+740.3%
Mar 10, 2026UpgradeMMaxim GroupHold → Buy$10+740.3%
Dec 05, 2024ResumedLLadenburg ThalmannBuy$13+992.4%
Jul 01, 2020InitiatedOOppenheimerOutperform
Jan 21, 2020ResumedRROTH CapitalBuy$10+740.3%
Sep 13, 2019InitiatedRROTH CapitalBuy
Dec 21, 2016InitiatedLLadenburg ThalmannBuy$2.70+126.9%

Peers

Mkt cap
TickerCompanyMkt cap
ATNMActinium Pharmaceuticals Inc50.93M
RADXRadiopharm Theranostics Ltd ADR13.74M
AKTSAktis Oncology Inc965.28M
MNPRMonopar Therapeutics Inc483.31M
TLXTelix Pharmaceuticals Ltd ADR3.31B
KPTIKaryopharm Therapeutics Inc0.39M
DRTSAlpha Tau Medical Ltd1.32B
GTBPGT Biopharma Inc8.14M
NBTXNanobiotix ADR1.67B
MRKRMarker Therapeutics Inc15.76M

Insider trading

3 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Longcor JarrodChief Operating OfficerMay 07 '26Buy2.888,68024,99820,451May 11 08:07 PM
CARUSO JAMES VChief Executive OfficerMay 07 '26Buy2.888,68024,99820,318May 11 08:05 PM
NEIS JOHNDirectorDec 12 '25Sale3.7019873210Dec 16 06:00 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 200
  • Cellectar Matches The Consensus Loss, But Slipping Timelines And A Tight Runway Leave The Funding Bridge Exposed (Earnings Whispers)
  • Cellectar Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates (GlobeNewswire)
  • Cellectar Biosciences to Present Three Posters Highlighting Durable Clinical Activity of Iopofosine I 131 in Waldenstrom Macroglobulinemia at the American Society of Hematology Annual Meeting and Exposition (GlobeNewswire) -6.11%
  • Cellectar Heads Into Third Quarter With Phase 3 Progress And Stock Far Below Warrant Trigger (Earnings Whispers) +7.38%
  • Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Tuesday, November 10, 2026 (GlobeNewswire)
  • Cellectar Biosciences Reports Case Study Highlighting Complete Response Lasting More Than Eight Years in Heavily Pretreated DLBCL Patient Treated with Iopofosine I 131 (GlobeNewswire)
  • Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenstrom Macroglobulinemia (GlobeNewswire)
  • Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Workshop for Waldenstrom Macroglobulinemia (GlobeNewswire)
  • Cellectar Biosciences Inc (CLRB) (Q2 2026) Earnings Call Highlights: Strong Clinical Data and ... (GuruFocus.com)
  • Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates (GlobeNewswire)
  • Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026 (GlobeNewswire)
  • Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers (GlobeNewswire)
  • Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenstrom Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting (GlobeNewswire) -5.41%
  • Cellectar Biosciences Inc (CLRB) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com) +8.84%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-10-0.460-0.557-0.5700.000.004
2026Q22026-08-13-0.570-0.520-0.5670.000.004
2026Q12026-05-14-1.330-1.885-1.3330.000.002
2025Q42026-03-040.650-1.225-1.2490.000.002
2025Q32025-11-13-1.410-2.527-1.4050.000.004
2025Q22025-08-14-3.390-3.719-3.3860.000.003
2025Q12025-05-13-4.200-4.900-4.3000.000.003
2024Q42025-03-13-2.100-10.575-1.5340.000.004
2024Q32024-11-18-12.000-9.900-11.1840.000.004
2024Q22024-08-13-9.525-9.600-5.4280.000.004
2024Q12024-05-14-22.200-14.799-27.2350.000.003
2023Q42024-03-27-12.300-17.100-12.1740.000.003
2023Q32023-11-16-26.082-17.100-36.4290.000.004
2023Q22023-08-14-21.900-19.101-21.9020.000.003
2023Q12023-05-04-22.800-24.900-22.8610.000.004
2022Q42023-03-09-16.500-32.250-23.0630.000.004

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-552-573-550.860.000.00
2020FY-228-243-228.550.000.00
2021FY-129-132.75-130.350.000.00
2022FY-121.5-99.150-135.180.000.00
2023FY-93.300-80.301-104.990.000.00
2024FY-36.600-48.375-41.8900.000.00
2025FY-8.350-9.271-8.3500.000.00
2026FY--2.392--0.00
2027FY--1.968--7.65
2028FY-0.228--68.20
2029FY-0.550--99.05
2030FY-1.570--155.22

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-103000.000.000.00
2026Q4S2026-08-133000.000.000.00
2026Q4S2026-07-103000.000.000.00
2026Q4S2026-05-142000.000.000.00
2026Q4S2026-03-041000.000.000.00
2026Q4R2026-11-10200-0.56-0.68-0.43
2026Q4R2026-10-27200-0.56-0.68-0.43
2026Q4R2026-08-13211-0.56-0.68-0.43
2026Q4R2026-07-28200-0.51-0.74-0.27
2026Q4R2026-05-14210-0.51-0.74-0.27
2026Q4R2026-03-09100-0.42-0.42-0.42
2026Q4R2025-11-22100-0.59-0.59-0.59
2026Q4R2025-11-13200-2.52-4.45-0.59
2026Q4R2025-11-11100-4.45-4.45-4.45

Estimate history

EPS, annual-3210-1567.959-550.857-228.552-130.353-135.179-104.988-41.89-8.354-3.6056
Period201720182019202020212022202320242025TTM
EPS, quarterly-11.184-1.534-4.3-3.386-1.405-1.249-1.333-0.567-0.457
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0000000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual0.0060.0160.0310.1510.2040.3130.6911.5364.2410.039
Period201720182019202020212022202320242025MRQ
Shares, quarterly1.3521.5361.5361.8123.1924.244.248.25210.039
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.010.210.290.190.150.230.210.190.08
Gross Profit-0.01-0.21-0.29-0.19-0.15-0.23-0.21-0.19-0.08
Selling, General and Administrative Excl. Other26.7722.7751.4938.7728.6723.9015.0813.9911.57
Research and Development16.1611.5026.1427.2718.2717.5910.149.006.75
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-26.78-22.98-51.78-38.96-28.81-24.13-15.29-14.18-11.66
Interest Expense0.000.000.000.000.00----
Unusual Expense-0.46-0.75-13.793.79-3.630.00-0.19-0.041.61
Net Income Before Taxes-25.85-21.79-44.52-42.83-31.85-24.12-15.09-14.09-13.24
Income Taxes0.000.000.07-0.06-0.060.000.000.000.00
Consolidated Net Income-25.85-21.79-44.58-42.77-31.79-24.12-15.09-14.09-13.24
Net Income From Continuing Operations-25.85-21.79-44.58-42.77-31.79-24.12-15.09-14.09-13.24
Net Income-25.85-21.79-44.58-42.77-31.79-24.12-15.09-14.09-15.48
EPS (Recurring)-1.50-8.56-49.69-98.48-145.99-130.35-230.52-552.03-1,453.57
EPS (Basic, Before Extraordinaries)-3.61-8.35-36.52-104.99-135.18-130.35-228.55-550.86-1,567.96
EPS (Diluted)-3.61-8.35-41.89-104.99-135.18-130.35-228.55-550.86-1,567.96
EBITDA-26.77-22.77-51.49-38.77-28.67-23.90-15.08-13.99-11.57
Non-Operating Income (Expense)0.470.44-6.53-0.08-6.670.010.010.040.03
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.972.263.381.901.151.120.470.870.72
Shares Outstanding10.044.241.540.690.310.200.150.030.02
Market Capitalization11.5311.5313.7827.4710.4540.5794.5221.127.34

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.040.04-0.110.050.050.060.060.07
Gross Profit-0.04-0.040.11-0.05-0.05-0.06-0.06-0.07
Selling, General and Administrative Excl. Other8.077.165.905.644.805.986.3412.68
Research and Development5.444.563.013.162.522.393.436.21
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-8.10-7.20-5.79-5.69-4.85-6.04-6.40-12.74
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.05-0.13-0.08-0.30-0.29-0.500.34-10.21
Net Income Before Taxes-7.97-6.93-5.65-5.30-4.44-5.45-6.60-2.29
Income Taxes0.000.000.000.000.000.000.000.07
Consolidated Net Income-7.97-6.93-5.65-5.30-4.44-5.45-6.60-2.36
Net Income From Continuing Operations-7.97-6.93-5.65-5.30-4.44-5.45-6.60-2.36
Net Income-7.97-6.93-5.65-5.30-4.44-5.45-6.60-2.36
EPS (Recurring)-0.45-0.57-1.35-1.30-1.47-3.60-4.14-6.19
EPS (Basic, Before Extraordinaries)-0.46-0.57-1.33-1.25-1.41-3.39-4.30-1.53
EPS (Diluted)-0.46-0.57-1.33-1.25-1.41-3.39-4.30-1.53
EBITDA-8.07-7.16-5.90-5.64-4.80-5.98-6.34-12.68
Non-Operating Income (Expense)0.180.130.060.100.110.090.140.24
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.520.430.450.570.570.570.561.17
Shares Outstanding10.048.254.244.243.191.811.541.54
Market Capitalization11.5322.2210.7712.5117.8812.8814.5313.78

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments13.2023.299.5619.8735.7057.1710.6113.3110.06
Short Term Receivables0.000.000.000.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets0.840.960.890.660.870.770.770.640.88
Total Current Assets14.0424.2510.4520.5336.5757.9411.3913.9510.94
Net Property, Plant & Equipment0.911.191.590.980.550.640.780.540.24
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets-------0.001.68
Other Assets0.030.030.030.080.080.080.080.560.01
Total Assets14.9825.4712.0821.5937.2058.6612.2515.0512.87
Short Term Debt Incl. Current Port. of LT Debt0.100.080.060.050.140.000.110.000.00
Accounts Payable1.444.115.622.561.421.431.281.541.87
Other Current Liabilities3.215.2019.688.892.442.131.390.080.24
Total Current Liabilities4.759.3925.3611.503.993.562.771.622.11
Long Term Debt0.310.410.490.550.170.300.420.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.000.000.170.00
Total Liabilities5.069.8025.8512.054.163.863.191.792.12
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value1.901.906.061.381.3820.041.152.531.00
Common Equity8.0213.77-19.848.1531.6634.767.9110.739.76
Total Shareholders Equity9.9215.68-13.789.5433.0554.799.0613.2610.75
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity9.9215.68-13.789.5433.0554.799.0613.2610.75
Total Liabilities & Stockholders Equity14.9825.4712.0821.5937.2058.6612.2515.0512.87
Book Value Per Share1.898.97-28.6926.06155.46229.47252.84680.521,757.11
Tangible Book Value Per Share1.898.97-28.6926.06155.46229.47252.84680.521,455.44
Full-Time Employees1111231512118715
Price to Book Ratio0.551.00-1.860.921.282.722.670.682.43
Return on Assets-107.74-237.45-254.09-108.15-50.33-42.57-103.23-94.82-96.20
Return on Equity-170.27-4,693.38-4,942.94-149.33-54.92-47.28-126.28-110.25-111.65
Return on Invested Capital-213.04-277.14--315.15-72.63-27.40-148.64-99.83-126.08
Quick Ratio2.962.580.411.789.1616.264.118.605.17
Current Ratio2.962.580.411.789.1616.264.118.605.17

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-25.85-21.79-44.58-42.77-31.79-24.12-15.09-14.09-13.24
Depreciation0.010.210.290.190.150.230.210.190.08
Other Funds (Non Cash)1.631.59-1.576.734.741.130.280.822.28
Funds from Operations-24.22-19.99-45.86-35.85-26.91-22.77-14.60-13.08-10.87
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-0.39-3.13-1.733.481.680.200.671.39-0.57
Cash from Operating Activities-24.61-23.12-47.58-32.38-25.22-22.57-13.93-11.69-11.44
Capital Expenditures-0.01-0.01-0.10-0.86-0.23-0.14-0.06-0.02-0.38
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.06
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.01-0.01-0.10-0.86-0.23-0.14-0.06-0.02-0.33
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock36.6513.0361.4122.949.611.2560.369.0215.02
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00-0.00
Sale of Common Pref Stock36.6513.0361.4122.949.611.2560.369.0215.03
Proceedsfrom Stock Options0.000.000.000.000.000.0359.729.0215.03
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.18-0.00-0.00
Change in Long Term Debt0.000.000.000.000.000.000.18-0.00-0.00
Issuance of Long Term Debt0.000.000.000.000.000.000.180.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.00-0.00-0.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities36.6513.0361.4122.949.611.2560.559.0215.02
Net Change in Cash12.03-10.0913.72-10.30-15.84-21.4646.55-2.703.25
Free Cash Flow-24.62-23.12-47.69-33.24-25.45-22.71-14.00-11.72-11.83
Preferred Dividends (Cash Flow)----0.00----
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments24.5833.998.3513.2012.5511.04
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets1.130.880.920.841.071.58
Total Current Assets25.7134.889.2714.0413.6212.62
Net Property, Plant & Equipment1.651.741.820.910.981.05
Total Investments and Advances0.000.000.000.000.000.00
Other Assets2.380.020.030.030.030.03
Total Assets29.7436.6411.1214.9814.6313.70
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.100.100.09
Accounts Payable5.735.224.724.424.014.68
Other Current Liabilities0.070.020.150.230.801.10
Total Current Liabilities5.805.244.874.754.915.87
Long Term Debt1.531.531.530.310.340.36
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities7.336.776.405.065.256.23
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.001.901.901.901.90
Common Equity22.4229.872.818.027.485.56
Total Shareholders Equity22.4229.874.729.929.387.47
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity22.4229.874.729.929.387.47
Total Liabilities & Stockholders Equity29.7436.6411.1214.9814.6313.70
Book Value Per Share2.233.620.661.892.343.07
Tangible Book Value Per Share2.233.620.661.892.343.07
Full-Time Employees---11--
Price to Book Ratio0.554.191.341.261.821.41
Return on Assets-116.54-88.70-153.46-107.74-72.62-134.97
Return on Equity-162.63-119.57-290.42-170.27-145.42-273.88
Return on Invested Capital-33.30-22.07-90.52-51.77-45.74-69.59
Quick Ratio4.446.661.902.962.772.15
Current Ratio4.446.661.902.962.772.15

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-7.97-6.93-5.65-5.30-4.44-5.45
Depreciation0.040.04-0.110.050.050.06
Other Funds (Non Cash)0.620.350.370.290.290.08
Funds from Operations-7.32-6.55-5.39-4.96-4.10-5.31
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-2.090.540.550.61-0.180.19
Cash from Operating Activities-9.41-6.01-4.85-4.34-4.28-5.12
Capital Expenditures0.000.00-0.00-0.010.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.00-
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.00-0.00-0.010.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.00---0.00-
Change in Capital Stock5E-0631.660.004.995.792.25
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock5E-0631.660.004.995.792.25
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities5E-0631.660.004.995.792.25
Net Change in Cash-9.4125.65-4.850.641.51-2.86
Free Cash Flow-9.41-6.01-4.85-4.35-4.28-5.12

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-302.35%0.2M9.3M87.83K
2026-10-152.84%0.3M9.3M71.68K
2026-09-301.79%0.2M9.3M58.68K
2026-09-152.06%0.2M9.3M70.29K
2026-08-311.80%0.2M9.3M89.30K
2026-08-141.74%0.2M9.3M123.59K
2026-07-312.33%0.2M7.5M1.06M
2026-07-152.66%0.2M7.5M1.07M
2026-06-302.48%0.2M7.8M1.04M
2026-06-150.73%0.1M7.8M1.00M
2026-05-293.44%0.3M7.5M1.00M
2026-05-1510.44%0.8M7.5M972.21K
2026-04-300.58%0.0M4.0M34.73K
2026-04-150.68%0.0M4.0M38.64K
2026-03-311.54%0.1M4.0M69.19K
2026-03-131.15%0.0M4.0M76.82K
2026-02-272.26%0.1M4.0M71.04K
2026-02-132.94%0.1M4.0M78.00K
2026-01-303.33%0.1M4.0M87.44K
2026-01-154.90%0.2M3.9M167.33K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-108-KCurrent report2026-11-10SEC
2026-11-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-08-14SCHEDULE 13GSEC
2026-08-14SCHEDULE 13GSEC
2026-08-14SCHEDULE 13GSEC
2026-08-14SCHEDULE 13GSEC
2026-08-13SCHEDULE 13GSEC
2026-08-138-KCurrent report2026-08-13SEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-04SCHEDULE 13GSEC
2026-07-104/A2026-07-08SEC
2026-07-108-KCurrent report2026-07-07SEC
2026-07-084Statement of changes in beneficial ownership of securities2026-07-07SEC
2026-07-084Statement of changes in beneficial ownership of securities2026-07-07SEC
2026-07-084Statement of changes in beneficial ownership of securities2026-07-07SEC
2026-07-084Statement of changes in beneficial ownership of securities2026-07-07SEC
2026-07-084Statement of changes in beneficial ownership of securities2026-07-07SEC
2026-07-084Statement of changes in beneficial ownership of securities2026-07-07SEC
2026-07-084Statement of changes in beneficial ownership of securities2026-07-07SEC
2026-07-084Statement of changes in beneficial ownership of securities2026-07-07SEC
2026-07-084Statement of changes in beneficial ownership of securities2026-07-08SEC
2026-06-093Initial statement of beneficial ownership of securities2026-05-18SEC
2026-06-05SCHEDULE 13GSEC
2026-06-02424B3SEC
2026-06-01EFFECTEffectiveness filing by commission orderSEC
2026-05-29CORRESPSEC
2026-05-29S-1/ASEC
2026-05-28DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-05-28DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-07-07SEC
2026-05-22UPLOADUpload SubmissionSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-0550.00K200
2026-040000
2026-030000
2026-020000
2026-010000
2025-12007321
2025-110000

Institutional holders

Manager% owned
Caligan Partners LP5.88%
Nantahala Capital Management, LLC5.51%
STEMPOINT CAPITAL LP4.44%
VANGUARD CAPITAL MANAGEMENT LLC4.10%
SILVERARC CAPITAL MANAGEMENT, LLC4.03%
Bleichroeder LP3.61%
Jupiter Topco LLC3.43%
BALYASNY ASSET MANAGEMENT L.P.2.75%
Empery Asset Management, LP2.37%
DIADEMA PARTNERS LP1.73%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.30%
VANGUARD EXTENDED MARKET INDEX FUND1.79%
Fidelity Extended Market Index Fund0.50%
Fidelity Series Total Market Index Fund0.11%
Fidelity Total Market Index Fund0.04%
Fidelity Nasdaq Composite Index Fund0.00%
Blackstone Alternative Multi-Strategy Fund0.00%

OakChart. CLRB. Cached 15 minutes.